research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
Search
for
Sort by
Research
450-480 / 1000+ results 
research AMINOPTERIN IN TREATMENT OF LEUKEMIA IN CHILDREN
Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.
research Amiodarone-Induced Toxic Epidermal Necrolysis; Nilotinib-Associated Cerebrovascular Disease and Stroke; Pisa Syndrome Caused by Paliperidone; Macroglossia Associated with Methylprednisolone; Aromatase Inhibitor-Induced “Male Pattern Baldness” in Women? Acute Liver Failure Due to Etodolac
Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
research Impact of Formulation Variables on Meloxicam spanlastics Preparation
Spanlastics are effective for delivering Meloxicam with improved stability and targeting.
research Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Progesterone, and Pyridoxine Hydrochloride in TrichoSolTM, A Natural Vehicle for Hair Solutions.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
research TRIDAX PROCUMBENS MEDICINE FOR LIFE: AN OVERVIEW
Tridax procumbens is a versatile herb with many health benefits.
research Recalcitrant widespread alopecia areata in a child treated successfully with oral methylprednisolone pulse therapy
Oral methylprednisolone pulse therapy helped an 11-year-old regrow 80% of his hair in six months.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Unraveling the Therapeutic Potential of Miracle Plant ‘Aftimoon’ in Disease Prevention and Treatment: A Comprehensive Review
Aftimoon has potential health benefits for various diseases and could be integrated into modern healthcare.
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research Systemic tofacitinib in paediatric alopecia areata
research A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib treatment for hair loss may worsen acne.
research Integrating systemic agents in clinic-based practice
Systemic agents like cyclosporine, methotrexate, and acitretin help manage psoriasis but have significant side effects.
research Combining 308-monochromatic excimer phototherapy with monthly IM triamcinolone acetonide for the treatment of resistant alopecia totalis
The combination therapy was effective and well-tolerated, especially in young patients.
![Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)](/images/research/d743d32f-3115-48ff-9697-2f2d56130701/small/14175.jpg)
research Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)
The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
research Actualización terapéutica en corticoesteroides tópicos: clasificación, usos clínicos y efectos colaterales
Topical corticosteroids are effective for skin conditions but can have side effects.
research STUDIED ON TOXICITY OF HYDROCORTISONE 17-BUTYRATE 21-PROPIONATE : 6. Subacute Toxicity in Dogs by Percutaneous Adminisration
Hydrocortisone 17-butyrate 21-propionate ointment caused reversible side effects like skin issues, weight gain, and organ changes in dogs.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Topical nitrogen mustard in the treatment of alopecia areata: a bilateral comparison study
Nitrogen mustard was not very effective for hair regrowth in alopecia areata and has potential skin cancer risk.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
research Compatibility of 17-a-estradiol, Caffeine, Clobetasol Propionate, Finasteride Melatonin, Metronidazole, Spironolactone, Tretinoin, and Triamcinolone in Trichosol, a Natural Vehicle for Hair Solutions.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.